Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0000950170-25-044099
Filing Date
2025-03-25
Accepted
2025-03-25 08:10:22
Documents
78
Period of Report
2024-12-31

Document Format Files

Seq Description Document Type Size
1 10-K atos-20241231.htm   iXBRL 10-K 2110818
2 EX-4.6 atos-ex4_6.htm EX-4.6 29656
3 EX-19.1 atos-ex19_1.htm EX-19.1 181499
4 EX-21.1 atos-ex21_1.htm EX-21.1 1996
5 EX-23.1 atos-ex23_1.htm EX-23.1 7592
6 EX-31.1 atos-ex31_1.htm EX-31.1 14269
7 EX-31.2 atos-ex31_2.htm EX-31.2 14103
8 EX-32.1 atos-ex32_1.htm EX-32.1 9012
9 EX-32.2 atos-ex32_2.htm EX-32.2 10031
10 GRAPHIC img96418037_0.jpg GRAPHIC 131956
11 GRAPHIC img264435894_0.jpg GRAPHIC 246040
12 GRAPHIC img264435894_1.jpg GRAPHIC 246040
  Complete submission text file 0000950170-25-044099.txt   8728985

Data Files

Seq Description Document Type Size
13 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT atos-20241231.xsd EX-101.SCH 1054204
81 EXTRACTED XBRL INSTANCE DOCUMENT atos-20241231_htm.xml XML 1078103
Mailing Address 10202 5TH AVENUE NE SUITE 200 SEATTLE WA 98125
Business Address 10202 5TH AVENUE NE SUITE 200 SEATTLE WA 98125 206.588.0256
ATOSSA THERAPEUTICS, INC. (Filer) CIK: 0001488039 (see all company filings)

EIN.: 264753208 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-35610 | Film No.: 25765938
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)